Blood Product Replacement in the Perinatal Period

Seminars in Perinatology

Volumn 31, Issue 4, 2007, Pages 262-271

  Wu, YanYun ^a   Stack, Gary ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

blood components; hemolytic disease of the newborn; neonatal alloimmune thrombocytopenia; perinatal transfusion; transfusion

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; WARFARIN;

ALPHA THALASSEMIA; ANTIBODY TITER; BLOOD GROUP TYPING; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CYTOMEGALOVIRUS; DISSEMINATED INTRAVASCULAR CLOTTING; ERYTHROCYTE; FETOMATERNAL TRANSFUSION; FETUS BLOOD SAMPLING; GRAFT VERSUS HOST REACTION; HUMAN; INTRAUTERINE BLOOD TRANSFUSION; NEWBORN HEMOLYTIC DISEASE; PERINATAL PERIOD; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; UMBILICAL CORD BLOOD;

BLOOD COMPONENT TRANSFUSION; BLOOD TRANSFUSION, INTRAUTERINE; ERYTHROBLASTOSIS, FETAL; FEMALE; FETAL DISEASES; HUMANS; INFANT, NEWBORN; PREGNANCY; THROMBOCYTOPENIA;

EID: 34548349345     PISSN: 01460005     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semperi.2007.05.004     Document Type: Review

References (48)

1. Judd W.J. Guidelines for Prenatal and Perinatal Immunohematology (2006), AABB Press, Bethesda, MD
2. American Academy of Pediatrics: Provisional Committee for Quality Improvement and Subcommittee on Hyperbilirubinemia. Practice parameter: management of hyperbilirubinemia in the healthy term newborn. Pediatrics 94 (1994) 558-565
3. Voak D., and Bowley C.C. A detailed serological study on the prediction and diagnosis of ABO hemolytic disease of the newborn (ABO HD). Vox Sang 17 (1969) 321-348
4. Wong E.C., and Luban N.L. Intrauterine, neonatal, and pediatric transfusion. In: Mintz P.D. (Ed). Transfusion Therapy: Clinical Principles and Practice. (ed 2) (2005), AABB Press, Bethesda, MD 159-201
5. Cassandra D.J., and Strauss R.G. Transfusion of neonates and pediatric patients. In: Hillyer C.D., Silberstein L.E., Ness P.M., et al. (Eds). Blood Banking and Transfusion Medicine: Basic Principles and Practice. (ed 2) (2007), Churchill Livingstone, Philadelphia, PA 510-522
6. Strauss R.G. Neonatal red blood cell, platelet, plasma, and neutrophil transfusions. In: Simon T.L., Dzik W.H., Snyder E.L., et al. (Eds). Rossi's Principles of Transfusion Medicine. (ed 3) (2002), Lippincott Williams & Wilkins, Philadelphia, PA 486-498
7. Brown K.A., Bissonnette B., and McIntyre B. Hyperkalemia during rapid blood transfusion and hypovolaemic cardiac arrest in children. Can J Anaesth 37 (1990) 747-754
8. Hall T.L., Barnes A., Miller J.R., et al. Neonatal mortality following transfusion of red cells with high plasma potassium levels. Transfus Apheresis Sci 33 (1993) 606-609
9. Eder A., Hume H., Pisciotto P., et al. Adverse effects of blood transfusion. In: Roseff S.D. (Ed). Pediatric Transfusion: A Physician's Handbook. (ed 2) (2006), AABB Press, Bethesda, MD 139-178
10. Stockman J.A., and de Alarcon P.A. Overview of the state of the art of Rh disease: history, current clinical management, and recent progress. J Pediatr Hematol Oncol 23 (2001) 385-393
11. Petz L.D., and Garratty G. Immune Hemolytic Anemias. (ed 2) (2004), Churchill Livingstone, Philadelphia, PA
12. Moise K.J. Management of Rhesus alloimmunization in pregnancy. Obstet Gynecol 100 (2002) 600-611
13. Bracey A.W., and Moise K.J. Hemolytic disease of the fetus or newborn: Treatment and prevention. In: Simon T.L., Dzik W.H., and Snyder E.L. (Eds). Rossi's Principles of Transfusion Medicine. (ed 3) (2002), Lippincott, Williams and Wilkins, Philadelphia, PA
14. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Clinical practice guideline. Pediatrics 114 (2004) 297-316
15. Poole J., and Daniels G. Blood group antibodies and their significance in transfusion medicine. Transfus Med Rev 21 (2007) 58-71
16. Reid M.E., and Lomas-Francis C. The Blood Group Antigen FactsBook. (ed 2) (2003)
17. Voak D. The serological specificity of the sensitizing antibodies in ABO heterospecific pregnancy of the group O mother. Vox Sang 14 (1968) 271-281
18. Ozolek J.A., Watchko J.F., and Mimouni F. Prevalence and lack of clinical significance of blood group incompatibility in mothers with blood type A or B. J Pediatr 125 (1994) 87-91
19. Vaughan J.I., Manning M., Warwick R.M., et al. Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. N Engl J Med 338 (1998) 338
20. Wagner T., Resch B., Reiterer F., et al. Pancytopenia due to suppressed hematopoiesis in a case of fatal hemolytic disease of the newborn associated with anti-K supported by molecular K1 typing. J Pediatr Hematol Oncol 26 (2004) 13-15
21. Babinszki A., Lapinski R.H., and Berkowitz R.L. Prognostic factors and management in pregnancies complicated with severe Kell alloimmunization: experiences of the last 13 years. Am J Perinatol 15 (1998) 695-701
22. Dhodapkar K.M., and Blei F. Treatment of hemolytic disease of the newborn caused by anti-Kell antibody with recombinant erythropoietin. J Pediatr Hematol Oncol 23 (2001) 69-70
23. Judd W.J. Practice guidelines for prenatal and perinatal immunohematology, revisited. Transfusion 41 (2001) 1445-1452
24. Bowman J. Rh-immunoglobulin: Rh prophylaxis. Best Pract Res Clin Haematol 19 (2006) 27-34
25. Hartwell E.A. Use of Rh immune globulin: ASCP practice parameter. Am J Clin Pathol 110 (1998) 281-282
26. Bianchi D.W., Avent N.D., Costa J.-M., et al. Noninvasive prenatal diagnosis of fetal Rhesus D. Obstet Gynecol 106 (2005) 841-844
27. Gall S.A., and Miller Jr. J.M. Rh isoimmunization: a 24 year experience at Duke University Medical Center. Am J Obstet Gynecol 140 (1981) 902-908
28. Van Dijk B.A., Dooren M.C., and Overbeeke M.A. Red cell antibodies in pregnancy: there is no "critical titre.". Transfus Med 5 (1995) 199-202
29. Oepkes D., Seaward P.G., Vandenbussche F.P.H.A., et al. Doppler ultrasonography versus amniocentesis to predict fetal anemia. N Engl J Med 355 (2006) 156-164
30. Kaplan C. Alloimmune thrombocytopenia of the fetus and the newborn. Blood Rev 16 (2002) 69-72
31. In: Klein H.G., and Anstee D.J. (Eds). Mollison's Blood Transfusion in Clinical Medicine. (ed 11) (2005), Blackwell Publishing, Malden, MA 581-584
32. In: Brecher M.E. (Ed). Perinatal Issues in Transfusion Practice: Technical Manual. (ed 15) (2005), AABB Press, Bethesda, MD 551-553
33. Mueller-Eckhardt C., Kiefel V., Grubert A., et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1 (1989) 363-366
34. Davoren A., Curtis B.R., Aster R.H., et al. Human platelet antigen-specific alloantibodies implicated in 1162 cases of neonatal alloimmune thrombocytopenia. Transfusion 44 (2004) 1220-1225
35. Williamson L.M., Hackett G., Rennie J., et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening. Blood 92 (1998) 2280-2287
36. L'Abbe D., Tremblay L., Filion M., et al. Alloimmunization to platelet antigen HPA-1a (PlA1) is strongly associated with both HLA-DRB3*0101 and HLA-DQB1*0201. Hum Immunol 34 (1992) 107-114
37. Saito S., Ota M., Komatsu Y., et al. Serologic analysis of three cases of neonatal alloimmune thrombocytopenia associated with HLA antibodies. Transfusion 43 (2003) 908-917
38. Thude H., Schorner U., Helfricht C., et al. Neonatal alloimmune thrombocytopenia caused by human leucocyte antigen-B27 antibody. Transfus Med 16 (2006) 143-149
39. Rousseau J., Goldman M., and David M. HPA-5b (Bra) neonatal alloimmune thrombocytopenia in Quebec: incidence and clinical outcome in 31 cases. Transfusion 44 (2004) 844-848
40. Mueller-Eckhardt C., Kiefel V., Grubert A., et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1 (1989) 363-366
41. Radder C.M., Brand A., and Kanhai H.H. Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it?. Vox Sang 84 (2003) 318-325
42. McFarland J.G. Detection and identification of platelet antibodies in clinical disorders. Transfus Apheresis Sci 28 (2003) 297-305
43. Berkowitz R.L., Kolb E.A., McFarland J.G., et al. Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. Obstet Gynecol 107 (2006) 91-96
44. Yinon Y., Spira M., Solomon O., et al. Antenatal noninvasive treatment of patients at risk for alloimmune thrombocytopenia without a history of intracranial hemorrhage. Am J Obstet Gynecol 195 (2006) 1153-1157
45. Thung S.F., and Grobman W.A. The cost effectiveness of empiric intravenous immunoglobulin for the antepartum treatment of fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol 193 (2005) 1094-1099
46. Sandler S.G., Johnson V.V., and Ramasethu J. Washed and volume-reduced blood components. In: Hillyer C.D., Silberstein L.E., Ness P.M., et al. (Eds). Blood Banking and Transfusion Medicine. Basic Principles and Practice. (ed 2) (2007), Churchill Livingstone, Philadelphia, PA
47. Kiefel V., Bassler D., Kroll H., et al. Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT). Blood 107 (2006) 3761-3763
48. Schallmoser K., Kutschera J., Macher S., et al. Delayed detectability of anti-HPA-3a by the MAIPA assay in a severe neonatal alloimmune thrombocytopenia, but successful transfusion of incompatible donor platelets: a case report. Vox Sang 91 (2006) 181-183